B. Braun Avitum s.r.o.
- Address
- Hodska 2378/85, 924 01 Galanta, Slovakia
Cardiovascular Diseases
The research at B. Braun Avitum s.r.o. includes studies in cardiovascular medicine focused on adults with atherosclerotic cardiovascular disease and related kidney disease. These trials are designed to assess whether new treatment options can help reduce serious heart-related events and improve long-term health outcomes.
- Reducing the risk of major cardiovascular events
- Evaluating therapies for people with cardiovascular disease and chronic kidney disease
- Exploring treatment options that may support both heart and kidney outcomes
This area reflects a strong interest in linking heart health with kidney protection, especially for patients facing overlapping chronic conditions.
Hemic and Lymphatic Diseases
Clinical trials in hematology at the site focus on anemia in people with chronic kidney disease, particularly those receiving dialysis. The goal is to compare treatments that may improve hemoglobin control and support better management of blood-related complications in this patient group.
- Managing anemia in dialysis patients
- Comparing therapies for hemoglobin level control
- Improving supportive care in chronic kidney disease
These studies are important for patients whose kidney disease affects blood health and overall quality of life.
Nutritional and Metabolic Diseases
Research in metabolic disease includes trials involving obesity, overweight, and chronic kidney disease. The studies are examining whether new therapies can help lower body weight-related risks while also supporting kidney and cardiovascular outcomes.
- Studying treatments for obesity and overweight
- Assessing kidney-related benefits in metabolic disease
- Testing therapies that may improve broader cardiometabolic health
Overall, this research area connects weight management, kidney function, and cardiovascular protection in a single clinical focus.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 353 other sites in Slovakia
Therapeutic Area Benchmark — Slovakia
Select a therapeutic area to compare against other sites in Slovakia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Slovakia
Market Share
Country: Slovakia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in B. Braun Avitum s.r.o.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of BAY 3283142 Efficacy and Safety in Reducing Albuminuria in Chronic Kidney Disease Patients: A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study | Bayer AG | Phase II | Not Recruiting | Aug 2024 | Nov 2025 |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bay 3283142 | 1 | Unknown | 2024-08-16 | 2024-08-16 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.